Beyond Cancer(TM) Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumors

Stock Information for Emerald Health Therapeutics Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Emerald Health Therapeutics Inc

Beyond Cancer Selected to Present on the Clinical Development of Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2024 American Society of Clinical Oncology Annual Meeting
Beyond Air® Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants
Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2024
Beyond Air® Schedules Third Fiscal Quarter 2024 Financial Results Conference Call and Webcast
Beyond Air® To Participate in the 35th Annual Piper Sandler Healthcare Conference
Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2024
Beyond Cancer(TM) Presents Positive First-in-Human Clinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
Beyond Air® Schedules Second Fiscal Quarter 2024 Financial Results Conference Call and Webcast

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.